Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 10/20 | 0.57 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358464 | 0.91 | KCNK3 (0.51) | KCNK3 | |
| SCHEMBL28818513 | 0.87 | KCNK3 (0.61) | KCNK3PTGDR2 | |
| SCHEMBL2074354 | 0.87 | KCNK3 (0.60) | KCNK3CTSSTRPM2 | |
| SCHEMBL29844211 | 0.82 | CTSS (0.46) | KCNK3CTSSTRPM2 | |
| SCHEMBL19358417 | 0.82 | HDAC1 (0.43) | KCNK3 | |
| SCHEMBL19358458 | 0.80 | OPRD1 (0.44) | KCNK3 | |
| SCHEMBL17328117 | 0.79 | KCNK3 (0.56) | KCNK3 | |
| SCHEMBL23605538 | 0.78 | KCNK3 (0.52) | KCNK3 | |
| SCHEMBL17328067 | 0.78 | POLB (0.45) | KCNK3 | |
| SCHEMBL17328047 | 0.77 | KCNK3 (0.49) | KCNK3CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| EP-4081509-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Zydus Lifesciences Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | KCNK3 2642/4885CTSS 2002/4885TRPM2 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.